![]() Oxurion Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. | ![]() Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | ![]() ANI Pharmaceuticals ANI Pharmaceuticals develops, manufactures and markets top quality prescription pharmaceuticals, made in the U.S.A. | |
Founding Date | Founding Date 1991 | Founding Date 2002 | Founding Date 1996 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Leuven, BE HQ Dublin 8, IE | Locations Baudette, US HQ Oakville, CA Baudette, US | |
Employees | Employees 785% increase | Employees 1,32324% increase | Employees 33813% increase |
Valuation ($) | Valuation ($) 626.1 k | Valuation ($) 36.5 b | Valuation ($) 1.2 b |
Financial | |||
Revenue (est.) | Revenue (est.) €555k (FY, 2025) | Revenue (est.) $3.7b (FY, 2025) | Revenue (est.) $883.4m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $677.2m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit €937k (FY, 2025) | Gross profit $3b (FY, 2025) | Gross profit N/A |
Net income | Net income (€3.7m) (FY, 2025) | Net income $313.7m (FY, 2025) | Net income N/A |
Funding | |||
Total funding raised | Total funding raised $ 3.9m | Total funding raised $ 1.5b | Total funding raised N/A |

Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View company
ANI Pharmaceuticals develops, manufactures and markets top quality prescription pharmaceuticals, made in the U.S.A.
View company